Conexeu Sciences Inc., a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, is pleased to announce that it has achieved a defining milestone in regenerative medicine with the first ever 3D-printed structures made entirely from its patented, functional extracellular matrix (ECM). Using its patented CXU™ platform, the Company has printed bovine-derived collagen-based scaffolds that behave like real tissue, establishing the foundation for personalized regeneration. This is a category-creating moment. Conexeu has moved regenerative medicine from “repairing tissue” to “tissue on demand.”
“The ability to print a functional collagen-based extracellular matrix that behaves like the architecture of real tissue, versus synthetic polymers or non-functional collagens, represents a new step for regenerative medicine,” said Dr. Claudia Chavez-Munoz, MD, PhD, Chief Science Officer of Conexeu. “By showing that CXU™ can print tissue structures, we are opening the door to truly personalized implants and grafts. Data has shown that CXU™ is a material that the body recognizes as its own. This could be a game changer in the fields of aesthetics and tissue reconstruction. If, and when, cleared by the FDA, this will place CXU™ at the forefront of all bioinks, being the first collagen-based extracellular matrix medical grade in the market.”
The breakthrough unlocks three high-value frontiers:
- Personalized implants and grafts – Craniofacial, breast, periodontal, and soft-tissue reconstruction, printed to match each patient.
- Vascular-supportive microenvironments – A functional matrix that supports neovascularization, critical for the long-term viability and function of cells.
- A single united platform for today’s clinic and tomorrow’s biofabrication. CXU™ now functions as both an injectable regenerative device and a printable ECM bioink, positioning the Company to enter the estimated $17.4B* of addressable markets – wound care, aesthetics, dental, reconstructive surgery, and 3D bioprinting.
With the global bioprinting market projected to exceed $6B by 20324, Conexeu is poised to become one of the foundational materials providers can access in a soon to be regenerative materials economy. 3D bioprinting enables us to create an implantable ECM that promotes vascularization just under the skin, supporting the long-term survival and function of cells.
“This breakthrough is a declaration,” said Miles Harrison, President & CEO of Conexeu. “The future of medicine is not just repairing tissue; it is creating it. With CXU™, we can inject regeneration today, and we can design regeneration for tomorrow. This is the dawn of personalized tissue on demand. CXU™ prints with precision but lives like biology and it sets the stage for a completely new era of human reconstruction.”
Key Features of CXU™ Bioink
- Printable Collagen-based ECM: successfully demonstrated in 3D bio-printed constructs.
- Thermosensitive performance: liquid at room temperature, self-crosslinking to a gel at ~37°C in ~10 minutes.
- Biological integration: biomimetic ECM architecture that promotes natural healing, allowing vasculogenesis, cell migration and cell differentiation.
- Clinical relevance: designed to replicate a wound care device, Ten Minute Tissue™ has shown faster wound closure and reduced scarring in pre-clinical studies.
- Regulatory Path: Conexeu’s Ten Minute Tissue™, the company’s first clinical product, is advancing toward its pre-510(k) submission targeted for Q3 2026, creating a clear commercial and regulatory path.
